Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Hoping To Position Simeprevir As Top Next-Gen Protease Inhibitor For HCV

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The pharma’s Janssen unit recently received notification of priority review from FDA for its protease inhibitor simeprevir NDA; meanwhile, the company waits to see if its compound will be used in combination with Bristol’s daclatasvir or Gilead’s sofosbuvir.

You may also be interested in...



Podcast: The Week In European Consumer Health Industry News, 8 March 2021

HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.

The Ins And Outs Of The EU's Approach To COVID-19 Vaccine Procurement & Exports

EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's  COVID-19 vaccine.

Harmonization Of The EU Regulatory Compliance Role: Many PRRC Issues To Be Clarified

Efforts are underway to create a harmonized approach among Persons Responsible for Regulatory Compliance who play a pivotal role in meeting the requirements of the EU MDR and IVDR. And liability issues are high on the agenda.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel